Affinage

ST3GAL1

CMP-N-acetylneuraminate-beta-galactosamide-alpha-2,3-sialyltransferase 1 · UniProt Q11201

Length
340 aa
Mass
39.1 kDa
Annotated
2026-06-10
32 papers in source corpus 19 papers cited in narrative 20 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

ST3GAL1 is a sialyltransferase that transfers sialic acid in α2,3-linkage onto the Galβ1,3GalNAc (core 1 / T-antigen) disaccharide of O-glycans, an activity reconstituted with recombinant enzyme on defined galactoside substrates and dependent on an intact catalytic domain (H299A mutant is inactive and non-tumorigenic) (PMID:27166796, PMID:41904587). Through this O-glycan sialylation it remodels the glycocalyx of numerous cell-surface and secreted proteins to tune receptor signaling, complement and immune evasion, and cell migration. It sialylates receptor tyrosine kinase pathway components to promote oncogenic signaling: AXL (driving dimerization and melanoma invasion) (PMID:33203881), GFRA1 (enabling GDNF-induced RET/AKT/ERα phosphorylation) (PMID:30040982), neuropilin-1 (increasing NRP1–EGFR binding affinity and EGF/EGFR-driven migration) (PMID:40024474), and integrin-α6β4 at defined O-glycosylation sites to activate FAK/SRC and metastasis (PMID:41904587); it also sialylates VEGF-A to drive FAK/paxillin signaling and EMT (PMID:40497576) and stabilizes MUCL1 to promote proliferation and metastasis (PMID:41770470). ST3GAL1-dependent sialoglycans engage the inhibitory immunoreceptors Siglec-7 and Siglec-9 to evade NK- and complement-mediated killing across prostate, liver, and breast cancers, including sialylation of CD55 that reduces C3 deposition (PMID:33177111, PMID:38448753, PMID:41961075). In immune and hematopoietic cells it sialylates CD18 to alter LFA-1 endocytic recycling and T-cell trafficking (PMID:37069398) and, redundantly with ST3GAL2, sialylates CD34, CD43, and GPIbα to support megakaryocyte proplatelet formation (PMID:35507766). ST3GAL1 transcription is controlled by multiple inducers and repressors including SOX2-GLI1, TGF-β1, GDNF, NRF2, and RANKL/c-FOS, with androgen-AR and estrogen-ERα signaling acting as negative regulators (PMID:33203881, PMID:30252131, PMID:41680135, PMID:41904587).

Mechanistic history

Synthesis pass · year-by-year structured walk · 9 steps
  1. 2016 High

    Establishing that human ST3GAL1 is itself a catalytically active enzyme on the core 1 disaccharide grounded all later substrate-specific claims in a defined biochemical activity.

    Evidence Recombinant human ST3GAL1 expressed in E. coli, in vitro sialylation assays on lactose, LacNAc, and Galβ1,3GalNAc substrates

    PMID:27166796

    Open questions at the time
    • No structural model of the catalytic or transmembrane domain
    • Donor/acceptor kinetics on native glycoprotein substrates not addressed
  2. 2018 Medium

    Linked ST3GAL1 to receptor-mediated growth signaling and to cytokine/oxidative phenotypes, moving it from an enzyme to a driver of cancer cell behavior.

    Evidence siRNA knockdown with GFRA1 substrate identification and RET/AKT/ERα phosphorylation readouts in breast cancer; retroviral overexpression in bladder cancer with transcriptomic and macrophage cytokine profiling

    PMID:29454317 PMID:30040982

    Open questions at the time
    • GFRA1 O-glycan structures not characterized by MS
    • Mechanism linking sialyl-T conversion to oxidative sensitivity unresolved
  3. 2019 High

    Showed ST3GAL1 sialylation can dampen rather than promote signaling, and identified a TGF-β1 feedback loop, refining the model of how it tunes pathways.

    Evidence LC-MS/MS O-glycan profiling of secreted vasorin, neuraminidase desialylation, Smad2/3 phosphorylation and HUVEC tube formation assays, MCF7 xenograft

    PMID:30252131

    Open questions at the time
    • Whether the same VASN sialoforms operate in vivo across tumor types not tested
    • Stoichiometry of VASN sialylation versus TGF-β1 binding not quantified
  4. 2020 High

    Defined ST3GAL1 as an oncogenic transcriptional target and a node controlling immune evasion and receptor activation through distinct substrates.

    Evidence SOX2-GLI1-induced ST3GAL1 with AXL substrate identification and metastasis assays (melanoma); CD55 O-glycan MS with C3 deposition/complement/ADCC assays (breast); MEG3→c-Jun→ST3GAL1 axis with EGFR sialylation and PI3K-AKT readouts (RCC)

    PMID:32737220 PMID:33177111 PMID:33203881

    Open questions at the time
    • Direct sialylation site mapping on AXL and EGFR not resolved
    • Context-dependent opposite effects on EGFR versus other RTKs unexplained
  5. 2022 High

    Genetic dissection in iPSC-derived cells showed ST3GAL1 acts redundantly with ST3GAL2 on shared core 1 substrates required for blood cell function.

    Evidence ST3GAL1/ST3GAL2 single and double knockout iPSC lines, PNA lectin binding, substrate identification, proplatelet formation assays

    PMID:35507766

    Open questions at the time
    • Relative contribution of each enzyme per substrate not fully partitioned
    • Physiological platelet phenotype in vivo not established
  6. 2023 High

    Identified CD18 as a substrate whose sialylation misroutes T-cell trafficking, establishing ST3GAL1 as a barrier to adoptive cell therapy with a defined rescue.

    Evidence In vivo CRISPR-Cas9 loss-of-function screen, CD18 substrate identification, LFA-1 endocytic recycling assays, βII-spectrin overexpression rescue in CAR T cells

    PMID:37069398

    Open questions at the time
    • Molecular link between CD18 sialylation and recycling machinery incompletely defined
    • Generalizability across T-cell subsets not established
  7. 2024 Medium

    Connected ST3GAL1 to Siglec-7/9 ligand synthesis as a mechanism of cancer immune evasion and provided standardized inhibitor kinetics.

    Evidence Siglec-7/9 ligand detection and immune evasion assays in prostate cancer with enzalutamide modulation; UGC fluorometric kinetic assay with soyasaponin-1 IC50 determination

    PMID:38448753 PMID:38645360

    Open questions at the time
    • Specific glycoprotein carriers of Siglec ligands not identified
    • Inhibitor selectivity in cells beyond in vitro kinetics untested
  8. 2025 Medium

    Extended the substrate repertoire (NRP1, VEGF-A, MUCL1) and reinforced the Siglec-mediated immune evasion model while implicating ST3GAL1 in therapy resistance.

    Evidence Co-IP/PLA substrate confirmation and binding affinity assays for NRP1-EGFR, VEGF-A FAK/paxillin signaling with bevacizumab synergy, MUCL1 stability with Lith-O-Asp inhibitor; Siglec-7 ligand and NK/ADCC assays in sorafenib-resistant HCC

    PMID:40024474 PMID:40497576 PMID:41770470 PMID:41961075

    Open questions at the time
    • Sialylation sites on NRP1 and VEGF-A not mapped
    • Whether MUCL1 stabilization is direct consequence of sialylation untested in cell-free system
  9. 2026 High

    Resolved transcriptional control nodes and proved catalytic dependence, mapping specific substrate O-glycosylation sites and linking ST3GAL1 to bone homeostasis.

    Evidence NRF2 ChIP-qPCR/luciferase promoter mapping, integrin-α6β4 site-directed mutagenesis with H299A catalytic-dead mutant and FAK/SRC readouts (CRC); RANKL→c-FOS induction, ERα-TRAF6 competition, and in vivo sialidase rescue in bone

    PMID:41680135 PMID:41904587

    Open questions at the time
    • Whether bone osteoclast substrate(s) of ST3GAL1 are defined
    • Integration of the many transcriptional regulators in a single cell context unresolved

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved which structural features dictate ST3GAL1 substrate selection across its diverse glycoprotein targets and how opposing signaling outcomes (e.g., AXL/RTK activation versus EGFR inhibition) are determined.
  • No structural basis for acceptor specificity
  • Context-dependent pro- versus anti-signaling effects unexplained
  • Sialylation site maps absent for most substrates

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0016740 transferase activity 3 GO:0140096 catalytic activity, acting on a protein 3
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-168256 Immune System 4 R-HSA-1643685 Disease 3 R-HSA-392499 Metabolism of proteins 2
Partners
AXLCD18CD55GFRA1MUCL1NRP1VASNVEGFA

Evidence

Reading pass · 20 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2020 ST3GAL1 is transcriptionally induced by the SOX2-GLI1 oncogenic complex in melanoma. ST3GAL1 drives melanoma metastasis by sialylating the receptor tyrosine kinase AXL, inducing AXL dimerization and activation, which in turn promotes melanoma invasion. In vitro and in vivo silencing experiments, glycosylated protein analysis, co-IP/pulldown to identify AXL as substrate, functional invasion and metastasis assays Nature communications High 33203881
2019 ST3GAL1 sialylates vasorin (VASN) on O-glycans (predominantly sialyl-3T and disialyl-T structures). Sialylation of VASN by ST3GAL1 reduces VASN binding to TGF-β1 by 2–3-fold; desialylation or ST3GAL1 silencing enhances VASN–TGF-β1 binding, dampening TGF-β1/Smad2/Smad3 signaling and tumor angiogenesis. TGF-β1 in turn transcriptionally activates ST3GAL1, forming a feedback loop. LC-MS/MS O-glycan profiling of secreted VASN, ST3GAL1 siRNA knockdown, neuraminidase desialylation, HUVEC tube formation assay, Smad2/Smad3 phosphorylation assay, MCF7 xenograft model International journal of cancer High 30252131
2020 ST3GAL1 mediates O-linked sialylation of CD55, shifting its O-glycan profile toward disialylated core 2 structures. This sialylation of CD55 reduces C3 deposition, protecting breast cancer cells from complement-mediated lysis and antibody-dependent cell-mediated cytotoxicity, thereby enabling immune evasion. ST3GAL1 siRNA knockdown, tandem mass spectrometry of N- and O-glycans from CD55, C3 deposition assay, complement-mediated lysis assay, ADCC assay Cancer immunology research High 33177111
2023 ST3GAL1 glycosylates CD18 (integrin β2) in activated CD8+ T cells, inducing spontaneous nonspecific tissue sequestration of T cells by altering LFA-1 endocytic recycling. This impairs cancer-specific migration of CAR T cells. βII-spectrin, a cytoskeletal LFA-1-associated molecule, reverses ST3GAL1-mediated nonspecific migration. In vivo CRISPR-Cas9 pooled loss-of-function screen, glycosylated protein analysis identifying CD18 as substrate, LFA-1 endocytic recycling assays, engineered CAR T cells with βII-spectrin overexpression, in vivo tumor models Nature immunology High 37069398
2018 ST3GAL1 mediates O-linked sialylation of GFRA1, which is required for GDNF-induced RET, AKT, and ERα phosphorylation in ER-positive breast cancer cells. ST3GAL1 silencing reduces GDNF-mediated signaling and cell proliferation. GDNF transcriptionally induces ST3GAL1, forming a positive feedback loop. ST3GAL1 siRNA knockdown, phosphorylation assays (RET, AKT, ERα), identification of GFRA1 as O-sialylation substrate, GDNF stimulation assays, cell proliferation assays Cancer letters Medium 30040982
2020 ST3GAL1 modulates EGFR sialylation to inhibit EGFR phosphorylation in renal cell carcinoma cells, affecting activation of the PI3K-AKT pathway. ST3GAL1 transcription is regulated by c-Jun (JUN), which binds the ST3GAL1 promoter; the lncRNA MEG3 controls c-Jun expression, thereby regulating ST3GAL1. Bioinformatics identification of c-Jun as ST3GAL1 promoter-binding transcription factor, MEG3 overexpression/knockdown, EGFR phosphorylation and PI3K-AKT pathway assays in RCC cells, in vivo xenograft Journal of cell science Medium 32737220
2016 Active recombinant human ST3GAL1 was expressed in E. coli and shown to catalyze transfer of sialic acid to galactoside substrates including lactose, N-acetyllactosamine, and benzyl 2-acetamido-2-deoxy-3-O-(β-d-galactopyranosyl)-α-d-galactopyranoside, confirming its enzymatic activity on type III disaccharides (Galβ1,3GalNAc). Recombinant protein expression in E. coli with solubility-enhancing fusions and disulfide bond optimization, in vitro sialylation assays on defined substrates PloS one High 27166796
2022 ST3GAL1 and ST3GAL2 both function as cellular O-glycan sialyltransferases acting on Galβ1,3GalNAc residues in hematopoietic and megakaryocytic cells. CD34, CD43, and GPIbα are major glycoprotein substrates shared by ST3GAL1 and ST3GAL2, while GPIIb O-sialylation relies predominantly on ST3GAL2. Loss of both ST3GAL1 and ST3GAL2 dramatically impairs megakaryocyte proplatelet formation. ST3GAL1/ST3GAL2 single and double knockout human iPSC lines, differentiation to HPCs and MKs, peanut agglutinin lectin binding assay, substrate glycoprotein identification, proplatelet formation assay Blood advances High 35507766
2018 ST3GAL1 overexpression in ovarian cancer cells increases cell growth, migration, invasion, and paclitaxel resistance in vitro and in vivo. TGF-β1 increases ST3GAL1 expression and induces EMT; ST3GAL1 knockdown inhibits TGF-β1-induced EMT marker expression. ST3GAL1 overexpression/knockdown in ovarian cancer cell lines, paclitaxel resistance assays in vitro and in mouse xenograft, TGF-β1 stimulation with EMT marker western blotting Cell death & disease Medium 30375371
2024 ST3GAL1 synthesizes sialoglycans capable of engaging the Siglec-7 and Siglec-9 immunoreceptors on immune cells, enabling prostate cancer immune evasion. ST3GAL1 levels inversely correlate with androgen signaling in prostate tumors. ST3GAL1 expression analysis in prostate tumor specimens, Siglec-7/9 ligand detection, functional immune evasion assays, modulation by enzalutamide Communications biology Medium 38448753
2025 ST3GAL1 sialylates neuropilin-1 (NRP1), and this sialylation increases NRP1 binding affinity toward EGFR at the molecular level. ST3GAL1 silencing impairs cell migration and wound healing linked to reduced CAPN2 activity as a consequence of diminished EGF/EGFR signaling. ST3GAL1 silencing also augments sensitivity to cetuximab-mediated cell lysis. Identification of NRP1 as ST3GAL1 substrate, co-IP/binding affinity assays between NRP1 and EGFR, ST3GAL1 siRNA knockdown, migration/wound healing assays, CAPN2 activity assay, cetuximab cytotoxicity assay The Journal of biological chemistry Medium 40024474
2026 RANKL activates c-FOS to drive ST3GAL1 transcription in osteoclasts, promoting osteoclastogenesis. Estrogen-bound ERα competes with TRAF6 and suppresses this c-FOS-dependent ST3GAL1 induction. In vivo sialidase treatment in estrogen-deficient models reduces osteoclast-mediated bone loss, mimicking estradiol effects. Transcriptional pathway analysis (c-FOS/ST3GAL1), ERα-TRAF6 competition assay, single-cell RNA sequencing of human bone, in vivo sialidase treatment in estrogen-deficient mouse models, serum sialic acid measurement in clinical cohort Bone research Medium 41680135
2026 NRF2 directly binds to two key regions on the ST3GAL1 promoter (−1107~−771 and −437~+195) to enhance ST3GAL1 transcription in colorectal cancer. ST3GAL1 mediates sialylation of integrin-α6β4 at specific O-glycosylation sites (ITGA6: S934, S937, T944; ITGB4: S1515, S1517, T1524), thereby activating downstream FAK/SRC signaling and promoting metastasis. Catalytic-domain mutant ST3GAL1 (H299A) has no tumor-promoting effect, confirming dependence on sialyltransferase activity. Dual luciferase mutation assay and ChIP-qPCR for NRF2-ST3GAL1 promoter interaction, lectin affinity immunoprecipitation, site-directed mutagenesis of O-glycosylation sites on integrin-α6β4, catalytic dead mutant (H299A), FAK/SRC phosphorylation assays, in vivo xenograft models Journal of translational medicine High 41904587
2025 ST3GAL1 directly binds MUCL1 and catalyzes its sialylation, increasing MUCL1 protein stability and promoting breast cancer cell proliferation, migration, invasion, and in vivo tumor growth and lung metastasis. These effects are reversed by sialyltransferase inhibitor Lith-O-Asp or MUCL1 knockdown. Co-IP demonstrating ST3GAL1-MUCL1 direct binding, sialylation assay, ST3GAL1 knockdown/overexpression, MUCL1 stability assay, Lith-O-Asp inhibitor treatment, in vivo tumor and metastasis models Human cell Medium 41770470
2025 ST3GAL1 directly glycosylates VEGF-A (confirmed by Duolink proximity ligation assay and co-immunoprecipitation) and activates FAK/paxillin signaling, promoting VEGF-A expression and EMT in endometrial cancer. ST3GAL1 inhibition with soyasaponin I (SsaI) reduces VEGF-A signaling and synergizes with bevacizumab in vivo. Duolink proximity ligation assay, co-immunoprecipitation, ST3GAL1 knockdown, SsaI pharmacological inhibition, in vitro migration/invasion assays, in vivo xenograft with bevacizumab combination International journal of gynaecology and obstetrics Medium 40497576
2026 ST3GAL1 knockdown significantly reduces Siglec-7 ligand expression on liver cancer cells (HCC), enhancing susceptibility to NK cell-mediated cytotoxicity and cetuximab-induced ADCC. Sorafenib-resistant HCC cells display hypersialylation with increased Siglec-7/9 ligands, conferring NK cell evasion that is reversed by ST3GAL1 silencing. ST3GAL1 siRNA knockdown, Siglec-7/9 ligand surface staining, NK cell cytotoxicity assays, ADCC assay, sorafenib-resistant cell lines Cancer immunology, immunotherapy Medium 41961075
2024 A universal glycosyltransferase continuous (UGC) assay revealed that ST3GAL1 inhibition by soyasaponin-1 is time-dependent, and ST3GAL1 is the most responsive of three tested glycosyltransferases (IC50 ~37 µM vs. 52 µM for FUT1 and 886 µM for C1GALT1). The kinetic parameters (Km) of ST3GAL1 were standardized using CMP as nucleotide donor. Continuous fluorometric glycosyltransferase assay (UGC), kinetic parameter determination, dose-response inhibition with soyasaponin-1 ACS omega Medium 38645360
2025 Androgen-androgen receptor (AR) signaling in the submandibular gland negatively regulates ST3GAL1 (and ST3GAL4), reducing MUC10 sialylation. This correlates with sex differences in oral microbiota composition, as female-preferring bacteria such as Akkermansia muciniphila can assimilate mucin by degrading terminal sialic acids. Neuraminidase treatment showing sialic acid contribution to MUC10 mobility on SDS-PAGE, androgen manipulation experiments, RT-PCR for ST3GAL1 expression, microbiota profiling Bioscience, biotechnology, and biochemistry Low 39572079
2025 AR and MYC cooperatively repress ST3GAL1 transcription in prostate cancer cells, limiting synthesis of Siglec-7 ligands. Supraphysiological androgen levels produce distinct glycopeptide profiles compared with physiological androgen levels, with O-glycans as major substrates for sialylation in prostate cancer. AR and MYC manipulation in prostate cancer cells, glycopeptide profiling, Siglec-7 ligand quantification, transcriptional regulation assays bioRxivpreprint Low
2018 ST3GAL1 overexpression in bladder cancer cells (converting T antigen to sialyl-T antigen) increases sensitivity to oxidative damage and modulates the transcriptome toward genomic instability. BCG challenge of ST3GAL1-overexpressing cells induces stronger macrophage secretion of IL-6, IL-1β, TNFα, and IL-10 compared to T-antigen-expressing cells. Retroviral transduction of ST3GAL1 cDNA into bladder cancer cells, whole-genome microarray, multiplex cytokine immunoassay of macrophage secretome, BCG challenge assays BMC cancer Medium 29454317

Source papers

Stage 0 corpus · 32 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2018 Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-β1-induced EMT and confers paclitaxel resistance in ovarian cancer. Cell death & disease 154 30375371
2020 ST3GAL1 is a target of the SOX2-GLI1 transcriptional complex and promotes melanoma metastasis through AXL. Nature communications 78 33203881
2019 Sialylation of vasorin by ST3Gal1 facilitates TGF-β1-mediated tumor angiogenesis and progression. International journal of cancer 60 30252131
2020 Sialylation of CD55 by ST3GAL1 Facilitates Immune Evasion in Cancer. Cancer immunology research 49 33177111
2023 ST3GAL1 and βII-spectrin pathways control CAR T cell migration to target tumors. Nature immunology 44 37069398
2018 Reciprocal feedback regulation of ST3GAL1 and GFRA1 signaling in breast cancer cells. Cancer letters 39 30040982
2024 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer. Communications biology 33 38448753
2016 Expression of Functional Human Sialyltransferases ST3Gal1 and ST6Gal1 in Escherichia coli. PloS one 25 27166796
2020 The lncRNA MEG3 mediates renal cell cancer progression by regulating ST3Gal1 transcription and EGFR sialylation. Journal of cell science 24 32737220
2016 Alpha-2, 3-sialyltransferases regulate the multidrug resistance of chronic myeloid leukemia through miR-4701-5p targeting ST3GAL1. Laboratory investigation; a journal of technical methods and pathology 24 27088512
2022 Overlapping and unique substrate specificities of ST3GAL1 and 2 during hematopoietic and megakaryocytic differentiation. Blood advances 19 35507766
2025 Targeting the ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) as a potential therapeutic strategy to overcome anti-VEGF resistance in endometrial cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 14 40497576
2018 Oxidative damage and response to Bacillus Calmette-Guérin in bladder cancer cells expressing sialyltransferase ST3GAL1. BMC cancer 13 29454317
2024 ST3GAL1 Promotes Malignant Phenotypes in Intrahepatic Cholangiocarcinoma. Molecular & cellular proteomics : MCP 11 39069074
2025 ST3GAL1 regulates cancer cell migration through crosstalk between EGFR and neuropilin-1 signaling. The Journal of biological chemistry 8 40024474
2024 Synthesis of α-Hydroxy-1,2,3-Triazole-linked Sialyltransferase Inhibitors and Evaluation of Selectivity Towards ST3GAL1, ST6GAL1 and ST8SIA2. ChemMedChem 7 38758134
2025 Androgens suppress the sialyltransferases ST3GAL1 and ST3GAL4 and modulate mucin 10 glycosylation in the submandibular gland, related to sex differences in commensal microbiota composition in mice. Bioscience, biotechnology, and biochemistry 4 39572079
2021 3'-Sulfo-TF Antigen Determined by GAL3ST2/ST3GAL1 Is Essential for Antitumor Activity of Fungal Galectin AAL/AAGL. ACS omega 4 34278124
2024 Universal Glycosyltransferase Continuous Assay for Uniform Kinetics and Inhibition Database Development and Mechanistic Studies Illustrated on ST3GAL1, C1GALT1, and FUT1. ACS omega 3 38645360
2023 miR-125a-5p regulates the sialyltransferase ST3GAL1 in murine model of human intestinal campylobacteriosis. Gut pathogens 3 37848994
2026 GCNT3 and ST3GAL1 expression correlates with HER2 status and MUC1/β-catenin/Cyclin D1 axis in breast cancer. BMC cancer 1 41857548
2025 [Sialyltransferase ST3GAL1 promotes malignant progression in glioma]. Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology 1 40260563
2025 Integrated tumour-immune cell response modelling of luminal a breast cancer details malignant signalling and ST3Gal1 inhibitor-induced reversal. Glycobiology 1 40492697
2025 ST3Gal1 modulates intestinal barrier function and impacts human ulcerative colitis. Molecular medicine reports 1 41416445
2024 Characterization of the molecular role that ST3GAL1 plays in porcine susceptibility to E. coli F18 infection. International journal of biological macromolecules 1 39029847
2022 Upregulation of sialyltransferases ST3Gal1 and ST6Gal1 promotes stabilization of erythrocyte mass and recovery of anemia in Trypanosoma brucei brucei-infected pigs. Research in veterinary science 1 35180660
2026 Estradiol regulates osteoclast sialylation via ST3Gal1 in postmenopausal osteoporosis. Bone research 0 41680135
2026 Fcer1g and St3gal1: Macrophage-associated angiogenesis biomarkers and therapeutic targets in sepsis-induced acute lung injury. PloS one 0 41758834
2026 The sialyltransferase ST3GAL1 mediates MUCL1 sialylation to exacerbate breast cancer progression. Human cell 0 41770470
2026 ST3GAL1 drives colorectal cancer metastasis by mediating NRF2-induced activation of the integrin-α6β4 signaling pathway via sialylation modification. Journal of translational medicine 0 41904587
2026 Targeting ST3GAL1 to downregulate ligands for the glycoimmune checkpoint Siglec-7 and reverse immune escape in hepatocellular carcinoma. Cancer immunology, immunotherapy : CII 0 41961075
2026 α2,3-Sialyltransferase (ST3Gal1) regulates endometrioid-type epithelial ovarian cancer cell migration and invasion via VEGF-R2/JAK2/STAT3 signaling cascades. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics 0 42080626

Missed literature

Know a paper Affinage missed for ST3GAL1? Flag it for the maintainers and the community.

No submissions yet.